Teprotumumab (Tepezza, Horizon Therapeutics), an insulin-like growth factor-1 receptor inhibitor, is a fully human monoclonal antibody developed to address a substantial unmet need for patients with thyroid eye disease. The drug blocks the inflammatory/autoimmune pathophysiology that underlies thyroid eye disease.